AVTX
Avalo Therapeutics, Inc.
$17.88
-0.67 (-3.61%)
At close · Jul 16
Market Cap
$939.87M
Shares
52,565,572
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.88
Open$18.33
Day$17.78–18.89
52W$4.81–24.27
Avg vol 30d1.8M
Short int12.3M · 23.4% float · 4.3d
Short vol41%
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+4%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
67%
mid-range
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+10%
trailing
YTD return
−2%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $16 — 50d above 200d
Institutional flow
Distributing
2 of 101 funds reported for Jun 30 · net -33.7K sh shares
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Rising
23.41% of float · ▲ +66.0% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+2312%
Y/Y
EPS growth
+72%
Y/Y
Free cash flow
$-51.6M
Balance sheet
$15.9M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $17 › 200d $16 — 50d above 200d
Institutional flow
Distributing
2 of 101 funds reported for Jun 30 · net -33.7K sh shares
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Rising
23.41% of float · ▲ +66.0% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $18 · 67%
52-wk high $24
vs 200-day avg +10%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTX
this stock
Avalo Therapeutics, Inc.
|
$939.87M | -1.5% | +2312.3% | — | 23.4% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTX | -10.4% | +24.8% | +10.0% | -3.3% | -1.5% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -10.3% | +24.7% | +1.1% | -3.8% | -11.6% |